CRNDE, a lncRNA and displays a very time- and tissue-specific pattern of expression, is the most upregulated lncRNA in gliomas ,which may associated with a "stemness" signature.
CRNDE, colorectal neoplasia differentially expressed (HGNC nomenclature)
LINC00180, LOC643911, "long intergenic non-protein coding RNA 180"
CRNDE, a lncRNA gene whose locus is low potential coding transcripts, is transcribed from chromosome 16 on the strand opposite to the adjacent IRX5 gene, with which it may share a bidirectional promoter.
The transcripts of CRNDE that have retained intronic sequence are highly enriched in the nucleus.
CRNDE is the most upregulated lncRNA in gliomas and in other cancers, it is associated with a “stemness” signature. In ESC, the function of CRNDE may be to suppress lineage-determining genes. During the differentiation of certain lineages (e.g., ectodermal cell types), CRNDE levels are known to rise further, perhaps in order to suppress genes that specify alternate cell fates. In cancers of tissues where CRNDE is aberrantly expressed, its high elevation may again help to suppress lineage markers and revert the cells to a less differentiated state.
CRNDE displays tissue-specific and temporal expression patterns, in that it has little to no expression in many normal adult tissues, such as colorectal mucosa, white blood cells, and liver, while tissues with high CRNDE expression include testis, breast, skin, parotid gland, and bronchial epithelium.CRNDE was differentially expressed in colorectal neoplasia relative to normal colorectal tissue. CRNDE expression is elevated in neoplastic diseases, especially cancers of the blood and brain.
While CRNDE expression is most often elevated in cancers, in some cases it is lower than in normal control tissue. For example, in contrast to clear cell carcinomas and Type I papillary tumors of the kidney, chromophobe tumors and oncocytomas show significantly downregulated expression of CRNDE.
CRNDE features high expression in high risk group of papillary thyroid cancer .
gliomas, colorectal cancer, acute myeloid leukemias(AML), hepatocelluar carcinoma(HCC), prostate cancer .
papillary thyroid cancer 
Labs working on this lncRNA
CSIRO Animal, Food and Health Sciences, Preventative Health Flagship, Commonwealth Scientific and Industrial Research Organisation, Sydney, NSW, Australia 
Department of Gastrointestinal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang.Autonomous Region, P.R. China 
- Ellis BC, Molloy PL, Graham LD. CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment[J]. Frontiers in genetics. 2012,3:270.
- Luo YH, Liang L, He RQ, Wen DY, Deng GF, Yang H, He Y, Ma W, Cai XY, Chen JQ, Chen G. RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.Oncotarget. 2017 May 26.